LAHORE: Haleon, a consumer healthcare company, announced on Tuesday that it is enhancing its production capacity of Panadol in Pakistan as part of a $12 million investment plan.

The initiative, launchedin2023andsetto be completed by the end of 2026, aims to strengthen the availability of theover-the-counter medicine.

Haleon CEO Qawi Naseer emphasised that the company`s focus is to empower people with accessible healthcare solutions.

During a ceremony, Mr Naseer further highlighted that Haleon`s demerger from GSK in 2022 has allowed for greater flexibility and autonomy to support local growth and innovation.